Goodwin represented Myrobalan Therapeutics on the matter. Myrobalan Therapeutics announced its $24 million Series A financing. The round was led by Co-win Ventures, with participation from...
Myrobalan Therapeutics’ $24 Million Series A Funding Round
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...